Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 11 | 2022 | 222 | 2.090 |
Why?
|
| Vaccination | 17 | 2023 | 664 | 1.370 |
Why?
|
| Whooping Cough | 4 | 2022 | 75 | 1.120 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 3 | 2022 | 95 | 1.040 |
Why?
|
| Diphtheria | 2 | 2022 | 14 | 0.950 |
Why?
|
| Tetanus | 2 | 2022 | 18 | 0.950 |
Why?
|
| Cataplexy | 1 | 2022 | 5 | 0.840 |
Why?
|
| Narcolepsy | 1 | 2022 | 6 | 0.840 |
Why?
|
| Bell Palsy | 1 | 2022 | 17 | 0.840 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 15 | 0.840 |
Why?
|
| Humans | 45 | 2023 | 18058 | 0.830 |
Why?
|
| Retrospective Studies | 17 | 2022 | 2498 | 0.770 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 251 | 0.670 |
Why?
|
| Asthma | 3 | 2020 | 302 | 0.610 |
Why?
|
| Blood Cells | 1 | 2016 | 4 | 0.580 |
Why?
|
| Cohort Studies | 10 | 2022 | 2631 | 0.570 |
Why?
|
| Eosinophils | 1 | 2016 | 9 | 0.570 |
Why?
|
| Infant | 10 | 2022 | 1212 | 0.550 |
Why?
|
| Adult | 20 | 2023 | 7696 | 0.550 |
Why?
|
| Female | 26 | 2022 | 12838 | 0.530 |
Why?
|
| Male | 23 | 2022 | 10173 | 0.480 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2021 | 62 | 0.480 |
Why?
|
| Seizures, Febrile | 4 | 2022 | 47 | 0.460 |
Why?
|
| Hospitalization | 7 | 2022 | 813 | 0.440 |
Why?
|
| Pandemics | 4 | 2022 | 293 | 0.420 |
Why?
|
| Aged | 17 | 2021 | 6258 | 0.410 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2021 | 552 | 0.390 |
Why?
|
| Natural Language Processing | 3 | 2022 | 53 | 0.380 |
Why?
|
| Influenza, Human | 3 | 2022 | 277 | 0.380 |
Why?
|
| Middle Aged | 17 | 2021 | 8073 | 0.380 |
Why?
|
| United States | 13 | 2022 | 4119 | 0.370 |
Why?
|
| Adolescent | 12 | 2023 | 3714 | 0.370 |
Why?
|
| Stroke | 3 | 2022 | 306 | 0.360 |
Why?
|
| Outpatients | 2 | 2021 | 113 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 397 | 0.350 |
Why?
|
| Herpes Zoster | 2 | 2021 | 86 | 0.330 |
Why?
|
| Hepatitis B Vaccines | 2 | 2020 | 46 | 0.310 |
Why?
|
| Incidence | 5 | 2022 | 1297 | 0.300 |
Why?
|
| Databases, Factual | 3 | 2019 | 330 | 0.290 |
Why?
|
| Infant, Newborn | 4 | 2022 | 852 | 0.280 |
Why?
|
| Case-Control Studies | 4 | 2023 | 1164 | 0.280 |
Why?
|
| Influenza Vaccines | 4 | 2019 | 284 | 0.280 |
Why?
|
| Young Adult | 11 | 2021 | 2479 | 0.270 |
Why?
|
| Measles Vaccine | 2 | 2022 | 21 | 0.250 |
Why?
|
| California | 9 | 2022 | 2327 | 0.240 |
Why?
|
| Prospective Studies | 4 | 2023 | 1294 | 0.220 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2022 | 3 | 0.220 |
Why?
|
| Models, Statistical | 2 | 2014 | 184 | 0.220 |
Why?
|
| Travel | 1 | 2022 | 9 | 0.220 |
Why?
|
| Corynebacterium | 1 | 2022 | 3 | 0.210 |
Why?
|
| Shoulder Injuries | 1 | 2022 | 2 | 0.210 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 10 | 0.210 |
Why?
|
| Tuberculosis | 1 | 2022 | 17 | 0.210 |
Why?
|
| Placenta | 1 | 2022 | 19 | 0.210 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 1956 | 0.210 |
Why?
|
| Orthopedic Procedures | 1 | 2022 | 6 | 0.210 |
Why?
|
| Anaphylaxis | 2 | 2019 | 15 | 0.210 |
Why?
|
| Child, Preschool | 8 | 2021 | 1428 | 0.200 |
Why?
|
| Measles | 1 | 2022 | 26 | 0.200 |
Why?
|
| Child | 8 | 2022 | 2519 | 0.190 |
Why?
|
| Politics | 1 | 2020 | 12 | 0.190 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 13 | 0.190 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 44 | 0.190 |
Why?
|
| Inpatients | 1 | 2021 | 79 | 0.190 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 20 | 0.180 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 357 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2020 | 43 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2021 | 120 | 0.180 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.180 |
Why?
|
| Ischemia | 1 | 2019 | 4 | 0.180 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 13 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.170 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 155 | 0.170 |
Why?
|
| Stress, Psychological | 1 | 2020 | 145 | 0.170 |
Why?
|
| Recurrence | 2 | 2016 | 186 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 170 | 0.170 |
Why?
|
| Hypertension | 2 | 2020 | 489 | 0.170 |
Why?
|
| Pregnancy | 2 | 2022 | 1484 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 445 | 0.170 |
Why?
|
| Dyslipidemias | 1 | 2019 | 63 | 0.170 |
Why?
|
| Risk | 3 | 2020 | 552 | 0.160 |
Why?
|
| Pain | 1 | 2019 | 84 | 0.160 |
Why?
|
| Disease Progression | 2 | 2016 | 255 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 205 | 0.150 |
Why?
|
| Telemedicine | 1 | 2021 | 187 | 0.150 |
Why?
|
| Medicare Part D | 1 | 2017 | 22 | 0.150 |
Why?
|
| Cost Sharing | 1 | 2017 | 40 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 177 | 0.150 |
Why?
|
| Cell Count | 1 | 2016 | 10 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1259 | 0.140 |
Why?
|
| Heart Failure | 1 | 2022 | 391 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 351 | 0.140 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.140 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 67 | 0.140 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 56 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 613 | 0.140 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 6 | 0.130 |
Why?
|
| Biomarkers | 1 | 2016 | 306 | 0.130 |
Why?
|
| Immunization Schedule | 3 | 2021 | 132 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 158 | 0.130 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.130 |
Why?
|
| Premature Birth | 1 | 2016 | 135 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 139 | 0.120 |
Why?
|
| Algorithms | 3 | 2022 | 235 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2014 | 84 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2014 | 73 | 0.120 |
Why?
|
| Biometry | 1 | 2014 | 13 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 45 | 0.120 |
Why?
|
| Obesity | 1 | 2020 | 839 | 0.120 |
Why?
|
| Risk Factors | 5 | 2020 | 3394 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 742 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2015 | 253 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1255 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 119 | 0.110 |
Why?
|
| Time Factors | 4 | 2019 | 1114 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 97 | 0.110 |
Why?
|
| HIV Infections | 1 | 2019 | 682 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 80 | 0.110 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 105 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 118 | 0.100 |
Why?
|
| Age Factors | 3 | 2020 | 945 | 0.100 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 90 | 0.090 |
Why?
|
| Fever | 2 | 2022 | 60 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 49 | 0.080 |
Why?
|
| Sex Factors | 2 | 2020 | 634 | 0.080 |
Why?
|
| Immunization Programs | 2 | 2020 | 68 | 0.070 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 70 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 618 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 892 | 0.070 |
Why?
|
| Maternal Age | 2 | 2016 | 79 | 0.060 |
Why?
|
| Managed Care Programs | 2 | 2017 | 356 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2016 | 113 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2019 | 734 | 0.060 |
Why?
|
| Travel-Related Illness | 1 | 2022 | 3 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2023 | 79 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 36 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 138 | 0.050 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2022 | 67 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 49 | 0.050 |
Why?
|
| Chickenpox Vaccine | 1 | 2022 | 101 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 15 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 42 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 118 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 57 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2022 | 150 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 94 | 0.040 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2019 | 14 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 35 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2020 | 280 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 134 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2019 | 47 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 53 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 132 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 138 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 160 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 274 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 454 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 324 | 0.040 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 29 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 15 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 56 | 0.030 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.030 |
Why?
|
| Bias | 1 | 2016 | 109 | 0.030 |
Why?
|
| Seasons | 1 | 2016 | 99 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 961 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 90 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 526 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 87 | 0.030 |
Why?
|
| Epilepsy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 49 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 92 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 161 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 319 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 119 | 0.030 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2013 | 22 | 0.030 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 19 | 0.030 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 12 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2013 | 66 | 0.030 |
Why?
|
| Quality Control | 1 | 2012 | 45 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2012 | 14 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 692 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 595 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 745 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 1137 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2014 | 504 | 0.020 |
Why?
|
Concepts
(187)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(30)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->